Replies to post #3920 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>how will physicians make money off follow-on biologics. Will they get paid at similar rate to inject FOBs or will this be a hurdle for prescribing?<

Good question. As NVS’ Omnitrope is now approved, NVS’ IR department ought to be able to give us an answer.